- Company
- Sanofi launches new dosage form of Praluent with reimb
- by Whang, byung-woo Apr 2, 2025 05:56am
- Sanofi announced on the 1st that a 300 mg dose form of its PCSK9 inhibitor Praluent (alirocumab) will be launched in April with health insurance reimbursement in Korea. According to this announcement, Praluent 300 mg may now be reimbursed when used in patients with primary hypercholesterolemia and mixed dyslipidemia who have been administ
- Company
- 'Rezurock' for cGVHD can be prescribed at 'Big 5' hospitals
- by Eo, Yun-Ho Apr 2, 2025 05:56am
- 'Rezurock,' a treatment for chronic graft-versus-host disease (cGVHD), is now being prescribed in general hospitals. According to industry sources, Sanofi Korea's ROCK2 inhibitor Rezurock (belumosudi) has passed the drug committees (DC) of the 'Big 5' tertiary general hospitals, including Samsung Medical Center, Seoul National University
- Company
- Vaxneuvance's 'immunogenicity' brings competitive edge
- by Whang, byung-woo Apr 2, 2025 05:56am
- With changes in the market for pneumococcal vaccines ahead, MSD Korea has begun to defend its market share by highlighting the “immunogenicity” of Vaxneuvance. Last year, the product was launched and added to the National Immunization Program (NIP), accelerating its market penetration. Celebrating its first year in the NIP, the company
- Company
- What are the remaining issues for Leclaza?
- by Moon, sung-ho Apr 1, 2025 05:53am
- The Leclaza-Rybrevant combination therapy has emerged as the new standard of care for lung cancer treatment and is now being actively implemented in South Korea's clinical settings. As results indicate improvements in progression-free survival (PFS) as well as overall survival (OS) compared to Tagrisso (osimertinib, AstraZeneca), Janssen has
- Company
- Korea is a strategic key R&D site for Boehringer Ingelheim
- by Whang, byung-woo Apr 1, 2025 05:52am
- Boehringer Ingelheim, which has proposed integrated management of cardiovascular-kidney-metabolic syndrome (CRM) with Jardiance at the forefront, has been drawing on innovation through research and development (R&D) investment. Boehringer Ingelheim has already invested more than EUR 5 billion (KRW 7.9666 trillion) in R&D in 2022 globally and
- Company
- Tepmetko granted reimb for METex14+ NSCLC
- by Whang, byung-woo Apr 1, 2025 05:52am
- On the 31st, Merck Korea announced that its Tepmetko (ingredient name: tepotinib), a treatment for MET-ex14 deletion-mutated non-small cell lung cancer, will be reimbursed as of the 1st of next month. Accordingly, Tepmetko is now covered by reimbursement for patients with locally advanced or metastatic non-small cell lung cancer with MET
- Company
- AbbVie Korea seeks to grow to ₩KRW 300B with biodrugs
- by Whang, byung-woo Mar 31, 2025 05:59am
- AbbVie Korea, which successfully passed on the risk of Humira (adalimumab) with its later products is aiming to make another leap forward with its innovative pipeline. The company is working to improve its capabilities by balancing the 3 key factors - sales growth, R&D, and social contribution. AbbVie Korea was established in 2013 as t
- Company
- Handok closer to commercialize new innovative drugs for BTC
- by Nho, Byung Chul Mar 31, 2025 05:59am
- Biliary tract cancer (BTC) is known for being difficult to treat. The five-year survival rate is 29.4%, which is the second lowest of all cancer types. Early diagnosis of BTC is difficult, and treatment for BTC is extremely limiting despite of the high risk. Fortunately, the situation is changing. New treatments are being approved in South K
- Company
- Novartis' 'Leqvio' for dyslipidemia lands at Big 5 hospitals
- by Eo, Yun-Ho Mar 31, 2025 05:58am
- The new drug Leqvio, a twice-yearly treatment for dyslipidemia, is now available for prescriptions at tertiary general hospitals. According to industry sources, Novartis Korea's siRNA drug Leqvio (inclisiran) passed the drug committees (DC) of the 'Big 5' hospitals, including Samsung Medical Center, Seoul National University Hospital, Asan
- Company
- Ono Pharma Korea appoints Kan Sato as new CEO
- by Eo, Yun-Ho Mar 31, 2025 05:58am
- Ono Pharma Korea has appointed a new leader. According to the related industry, Ono Pharma Korea recently appointed Sato Kano as its new CEO following the resignation of former CEO, Ho-jin Choi. Choi, who led the company for four and a half years since his appointment in October 2020, has stepped down. Choi joined Ono Pharmaceutical
